FRANKFURT, July 18 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback